Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
2000 9
2001 24
2002 38
2003 64
2004 50
2005 103
2006 82
2007 80
2008 82
2009 93
2010 112
2011 99
2012 110
2013 109
2014 104
2015 144
2016 133
2017 128
2018 129
2019 126
2020 125
2021 113
2022 139
2023 119
2024 132
2025 144
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,317 results

Results by year

Filters applied: . Clear all
Page 1
Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, Wang R, Liu L, Zhao F, Wang S. Qi Q, et al. Int J Clin Pharmacol Ther. 2015 Oct;53(10):803-10. doi: 10.5414/CP202396. Int J Clin Pharmacol Ther. 2015. PMID: 26329348
These results revealed a significant difference between esomeprazole vs. omeprazole (RR=1.06, 95% CI [1.01, 1.10], I2=72%, p=0.01) by subgroup according to dosage by random effects model, and a significant difference between esomeprazole 40 mg vs. omeprazole 20 mg ( …
These results revealed a significant difference between esomeprazole vs. omeprazole (RR=1.06, 95% CI [1.01, 1.10], I2=72%, p=0.01) by …
Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E, Kim S, Kim B, Kim B, Kim Y, Park SS, Song GS, Yu KS, Jang IJ, Lee S. Yang E, et al. Br J Clin Pharmacol. 2022 Jul;88(7):3288-3296. doi: 10.1111/bcp.15268. Epub 2022 Feb 23. Br J Clin Pharmacol. 2022. PMID: 35146797 Free PMC article. Clinical Trial.
Tegoprazan exhibited night-time acid suppression for slightly but not significantly longer than vonoprazan, and greater than esomeprazole; % time at pH 4 at night was 66.0%, 60.5% and 36.1% for tegoprazan, vonoprazan and esomeprazole, respectively. Night-time acid s …
Tegoprazan exhibited night-time acid suppression for slightly but not significantly longer than vonoprazan, and greater than esomeprazole …
Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.
Lee KN, Lee OY, Chun HJ, Kim JI, Kim SK, Lee SW, Park KS, Lee KL, Choi SC, Jang JY, Kim GH, Sung IK, Park MI, Kwon JG, Kim N, Kim JJ, Lee ST, Kim HS, Kim KB, Lee YC, Choi MG, Lee JS, Jung HY, Lee KJ, Kim JH, Chung H. Lee KN, et al. World J Gastroenterol. 2022 Nov 28;28(44):6294-6309. doi: 10.3748/wjg.v28.i44.6294. World J Gastroenterol. 2022. PMID: 36504556 Free PMC article. Clinical Trial.
RESULTS: Of the 263 randomized, 218 completed the study per protocol (fexuprazan 40 mg, n = 107; esomeprazole 40 mg, n = 111). Fexuprazan was non-inferior to esomeprazole regarding the healing rate at week 8 [99.1% (106/107) vs 99.1% (110/111)]. ...CONCLUSION: Fexup …
RESULTS: Of the 263 randomized, 218 completed the study per protocol (fexuprazan 40 mg, n = 107; esomeprazole 40 mg, n = 111). Fexupr …
Reply.
Cluver C, Hannan N, Tong S. Cluver C, et al. Am J Obstet Gynecol. 2019 Feb;220(2):207. doi: 10.1016/j.ajog.2018.10.009. Epub 2018 Oct 10. Am J Obstet Gynecol. 2019. PMID: 30315783 No abstract available.
Intravenous esomeprazole.
Keating GM, Figgitt DP. Keating GM, et al. Drugs. 2004;64(8):875-82; discussion 883. doi: 10.2165/00003495-200464080-00008. Drugs. 2004. PMID: 15059043
In addition, a similar level of gastric acid control occurred with intravenous esomeprazole 40 mg administered by infusion or injection once daily for 10 days. In healthy volunteers, intravenous esomeprazole provided faster and more effective gastric acid control th …
In addition, a similar level of gastric acid control occurred with intravenous esomeprazole 40 mg administered by infusion or injecti …
Introduction.
Illueca M. Illueca M. J Pediatr Gastroenterol Nutr. 2015 Jul;60 Suppl 1:S1. doi: 10.1097/01.mpg.0000466914.65742.da. J Pediatr Gastroenterol Nutr. 2015. PMID: 26422092 No abstract available.
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM, Jiang XT, Chen CC, Luo JC, Bair MJ, Chen PY, Chou CK, Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Liou JM, et al. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):228-241. doi: 10.1016/S2468-1253(22)00384-3. Epub 2022 Dec 19. Lancet Gastroenterol Hepatol. 2023. PMID: 36549320 Clinical Trial.
Adult patients (age 20 years) with persistent H pylori infection after first-line clarithromycin-based therapy were randomly assigned (1:1, permuted block sizes of four) to receive levofloxacin-based sequential quadruple therapy for 14 days (EAML14; esomeprazole 40 mg and …
Adult patients (age 20 years) with persistent H pylori infection after first-line clarithromycin-based therapy were randomly assigned (1:1, …
Naproxen/esomeprazole (Vimovo).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2010 Sep 20;52(1347):74-5. Med Lett Drugs Ther. 2010. PMID: 20847717 No abstract available.
A Multinational Randomized Trial of Mega-Dose Esomeprazole as Anti-Inflammatory Agent in Sepsis.
Monti G, Carta S, Kotani Y, Bruni A, Konkayeva M, Guarracino F, Yakovlev A, Cucciolini G, Shemetova M, Scapol S, Momesso E, Garofalo E, Brizzi G, Baldassarri R, Ajello S, Isirdi A, Meroi F, Baiardo Redaelli M, Boffa N, Votta CD, Borghi G, Montrucchio G, Rauch S, D'Amico F, Pace MC, Paternoster G, Vitale F, Giardina G, Labanca R, Lembo R, Marmiere M, Marzaroli M, Nakhnoukh C, Plumari V, Scandroglio AM, Scquizzato T, Sordoni S, Valsecchi D, Agrò FE, Finco G, Bove T, Corradi F, Likhvantsev V, Longhini F, Konkayev A, Landoni G, Bellomo R, Zangrillo A; PPI-SEPSIS Study Group. Monti G, et al. Crit Care Med. 2025 Aug 1;53(8):e1554-e1566. doi: 10.1097/CCM.0000000000006720. Epub 2025 May 29. Crit Care Med. 2025. PMID: 40439536 Clinical Trial.
We tested the hypothesis that mega-dose esomeprazole therapy would reduce organ dysfunction in patients with sepsis or septic shock. ...We also conducted a mechanistic study of the in vitro effects of esomeprazole in sepsis. We randomized 307 patients and assigned 1 …
We tested the hypothesis that mega-dose esomeprazole therapy would reduce organ dysfunction in patients with sepsis or septic shock. …
Esomeprazole: a proton pump inhibitor.
Vachhani R, Olds G, Velanovich V. Vachhani R, et al. Expert Rev Gastroenterol Hepatol. 2009 Feb;3(1):15-27. doi: 10.1586/17474124.3.1.15. Expert Rev Gastroenterol Hepatol. 2009. PMID: 19210109 Review.
Esomeprazole is available in both oral and intravenous formulations. A number of studies have compared esomeprazole with other PPIs. While differences supporting esomeprazole have been reported, the magnitude of differences has been variable and of uncertain …
Esomeprazole is available in both oral and intravenous formulations. A number of studies have compared esomeprazole with other …
2,317 results